# Anatomic Correlation of NMDA and <sup>3</sup>H-TCP-Labeled Receptors in Rat Brain

William F. Maragos, John B. Penney, and Anne B. Young

Department of Neurology and the Neuroscience Program, University of Michigan, Ann Arbor, Michigan 48104

Using quantitative autoradiography, we have compared the regional distribution of N-methyl-p-aspartate (NMDA) receptors labeled with <sup>3</sup>H-glutamate and dissociative anesthetic binding sites labeled with <sup>3</sup>H-N-(1-[2-thienyl]cyclohexyl)3,4piperidine (3H-TCP). Binding of both ligands was highest in the hippocampal formation, with high concentrations in a number of cortical and olfactory regions. Intermediate amounts of binding for both ligands were measured in several thalamic and basal telencephalic structures. Very little binding was observed in the hypothalamus, some deep forebrain regions, and most brain-stem structures. Linearregression analysis comparing the binding at both sites revealed a marked concordance (R = 0.95; p < 0.001; Pearson product-moment). The granule cell layer of the cerebellum was the only region in which this concordance was not observed. Scatchard analysis of <sup>3</sup>H-glutamate binding to NMDA receptors in stratum radiatum of hippocampal formation revealed an apparent single binding site with a  $B_{max}$  of 9.78  $\pm$ 0.84 pmol/mg protein and  $K_D$  of 158  $\pm$  37 nm.  $^3\text{H-TCP}$  also bound to an apparent single site with a  $\emph{B}_{\text{max}}$  of 2.07  $\pm$  0.16 pmol/mg protein and  $K_p$  of 127  $\pm$  30 nm. Our results are consistent with the hypothesis that the dissociative anesthetic binding site is linked to the NMDA receptor, and the data suggest that there are approximately 4-5 NMDA binding sites for each dissociative anesthetic binding site.

The dissociative anesthetics—e.g., phencyclidine (PCP), ketamine, and related drugs—comprise a novel group of drugs that were originally used as surgical anesthetics (Greifenstein et al., 1958; Johnstone et al., 1959; Corssen and Domino, 1966). More recently, these drugs have become major substances of abuse (Burns and Lerner, 1976). Drugs of this class produce psychotomimetic effects in humans, including thought disorders, distortions of body image, depersonalization, mania, and sometimes catatonia (Luby et al., 1959; Domino, 1964). These behaviors are similar to those seen in chronic schizophrenia, and this observation had led some to postulate a common underlying mechanism.

Recently, electrophysiological studies have indicated that the dissociative anesthetics antagonize the effects of N-methyl-papartate (NMDA)-sensitive glutamate receptors in the cerebral

Received Jan. 29, 1987; revised June 15, 1987; accepted July 29, 1987.

Copyright © 1988 Society for Neuroscience 0270-6474/88/020493-09\$02.00/0

cortex (Harrison and Simmonds, 1985; Thomson et al., 1985), hippocampal formation (Raja and Guyenet, 1982), and spinal cord (Anis et al., 1983). The NMDA receptor is one of at least 3 receptor subtypes at which the excitatory amino acid, glutamate, is believed to exert its action (Watkins and Evans, 1981). NMDA receptors occur throughout the mammalian CNS (Greenamyre et al., 1985; Monaghan and Cotman, 1985). Although the exact behavioral role of these receptors is unknown. they appear to be involved in learning (Morris et al., 1986), memory (Collingridge, 1985), and possibly epilepsy (Meldrum, 1985). At the molecular level, NMDA receptors are linked to a voltage-dependent cation channel (Engberg et al., 1978; MacDonald et al., 1982; Flatman et al., 1983). This channel is gated by Mg<sup>2+</sup> (Mayer et al., 1984; Nowak et al., 1984), which has been shown to inhibit the actions of NMDA noncompetitively (Harrison and Simmonds, 1985). The dissociative anesthetics exert inhibitory actions on the channel similar to Mg<sup>2+</sup> (Duchen et al., 1985; Honey et al., 1985), perhaps through an allosteric site on the NMDA receptor-channel complex (Harrison and Simmonds, 1985; Martin and Lodge, 1985).

If NMDA receptors and dissociative anesthetic (PCP) recognition sites are linked, one prediction is that they should have a similar anatomical distribution. Recently, autoradiographic assays have been developed in several laboratories to visualize both NMDA (Greenamyre et al., 1985; Monaghan and Cotman, 1985) and dissociative anesthetic receptor distribution (Quirion et al., 1981; Sircar and Zukin, 1985; Gundlach et al., 1986; Vignon et al., 1986). Using <sup>3</sup>H-glutamate and <sup>3</sup>H-N-(1-[2-thienyl]cyclohexyl)3,4-piperidine (3H-TCP), we have applied the technique of quantitative autoradiography to investigate the distribution of NMDA and dissociative anesthetic recognition sites, respectively, in the rat CNS (Maragos et al., 1986). 3H-TCP was selected as the ligand since it binds with higher affinity (Vignon et al., 1983) and 50-100 times greater specificity (Largent et al., 1986) to the dissociative anesthetic site than PCP or other PCPlike drugs.

### **Materials and Methods**

Male Sprague-Dawley rats weighing approximately 200 gm were used in this study. On the day of the experiment, animals were decapitated, and the brains were rapidly removed and immediately frozen on dry ice. The frozen brains were mounted on aluminum chucks and equilibrated to the cryostat temperature ( $-17^{\circ}$ C) for a half-hour prior to sectioning. Assays of each receptor class were carried out on alternate 20  $\mu$ m sections thaw-mounted onto gelatin-coated slides.

<sup>3</sup>H-TCP binding assay. <sup>3</sup>H-TCP binding using autoradiographic techniques has been examined by several groups (Sircar and Zukin, 1985; Gundlach et al., 1986; Largent et al., 1986). In these studies, the pharmacology, distribution, and physiochemical properties of binding have been examined, and they fit closely with the known physiology and

Thanks to Genell Fries for preparation of the manuscript and to Zane Hollingsworth and Darrell DeBowey for technical assistance. Supported by USPHS Grants NS15655, NS19613, AG06155, and the ADRDA.

Correspondence should be addressed to Dr. John B. Penney, Neuroscience Laboratory Building, University of Michigan, 1103 East Huron, Ann Arbor, MI 48101.

behavior of dissociative anesthetics. In initial experiments, we found that the association rate of  ${}^{3}\text{H-TCP}$  with the receptor at  ${}^{4}\text{C}$  was  $6.1\pm2.0\times10^{3}~\text{M}^{-1}~\text{sec}^{-1}$ . The dissociation rate was determined as  $8.8\pm3.0\times10^{-4}~\text{sec}^{-1}$ . The ratio of  $k_{-1}/k_{1}$  corresponded closely to the equilibrium-saturation constant,  $K_{D}=127\pm30~\text{nm}$ . This finding suggested that the labeled ligand was binding via a bimolecular reaction and was unlikely to be sequestered by transport processes, as has been suggested for the binding of some labeled ligands (Kessler et al., 1987). The offrate of  ${}^{3}\text{H-TCP}$  was slower than that of  ${}^{3}\text{H-glutamate}$ , and rinse of  $3\times1$  min optimized the specific to nonspecific ratios. We also confirmed the pharmacological specificity of  ${}^{3}\text{H-TCP}$  binding as described by others (Largent et al., 1986; W. F. Maragos, unpublished observations).

For routine assays, sections were washed for 30 min in cold 50 mm Tris-acetate, pH 7.4, and dried. For regional distribution studies, sections were incubated for 45 min in the same buffer at 4°C, containing 1 mм magnesium acetate and 20 nм <sup>3</sup>H-TCP (52.9 Ci/mmol, New England Nuclear Corporation). Magnesium acetate was added to the incubation medium, as this has been shown in preliminary experiments to enhance binding (D. C. M. Chu, unpublished observations). Nonspecific binding was determined by incubating slides with <sup>3</sup>H-TCP in the presence of 20 µm unlabeled PCP. Saturation studies were carried out in 2 parts. For the lower concentrations, sections were incubated for 45 min in cold buffer containing concentrations of <sup>3</sup>H-TCP ranging from 1 to 20 nm. Nonspecific binding was determined for each point in the presence of 20  $\mu M$  PCP. For higher concentrations, sections were incubated for 45 min in 20 nm <sup>3</sup>H-TCP diluted with varying amounts of nonradioactive TCP ranging from 30 to 980 nm. For this group of sections, nonspecific binding was determined in 20 nm <sup>3</sup>H-TCP in the presence of 20 µm PCP. Following incubation, sections were washed 3 times for 1 min each in cold buffer containing magnesium and rapidly dried.

NMDA receptor assay. NMDA receptors were labeled with L-3Hglutamate under conditions that have been shown to select for binding to NMDA receptors (Greenamyre et al., 1985). Under these conditions, the kinetics of glutamate binding were identical to those determined for <sup>3</sup>H-glutamate binding in the presence of calcium and chloride (Greenamyre et al., 1983). For regional distribution studies, sections were washed for 30 min in cold 50 mm Tris-acetate, pH 7.4, and dried. Sections were then incubated in the same buffer at 4°C containing 200 пм L-3H-glutamate (specific activity, 5.24 Ci/mmol; Amersham Corporation) and 1 µM quisqualic acid. This concentration of quisqualate has been determined to inhibit >90% of the non-NMDA glutamate receptors. For saturation studies, sections were incubated at 4°C in buffer containing 26 nm L-3H-glutamate (39 Ci/mmol) diluted with varying concentrations of nonradioactive glutamate ranging from 25 nm to 10 μM. Following a 45 min incubation all sections were rapidly rinsed 3 times with 3 ml of cold buffer followed by 1 rinse with a solution of cold glutaraldehyde and acetone (1:19, vol/vol) and rapidly dried. The total rinse time of this assay did not exceed 10 sec. Nonspecific binding was determined in the presence of 100 μm NMDA or 1 mm glutamate, and values were similar using either displacer. Depending on the region, nonspecific binding varied from 5 to 50% of total glutamate binding.

Autoradiography and data analysis. Sections were placed in an x-ray cassette and apposed to a piece of Ultrofilm <sup>3</sup>H (LKB). A complete set of radioactive standards calibrated against brain paste with known amounts of tritium was co-exposed with each film. Following a 3 week exposure at 4°C, films were developed in Kodak D19, fixed, and airdried. Autoradiographic analysis was carried out using previously described methods (Pan et al., 1983). At least 15 readings were made for each region studied. Anatomical areas were determined using the atlases of Paxinos and Watson (1982) and Zilles (1985). Scatchard analyses of saturation data were constructed using the computer program LIGAND (Munson and Rodbard, 1980). Binding of the 2 ligands to the various areas of the brain was compared with the Pearson product-moment coefficient and linear-regression analysis.

## Results

The binding pattern of L-3H-glutamate-labeled NMDA receptors and 3H-TCP recognition sites was nearly identical in all forebrain regions (Fig. 1). When the bound values for NMDA and TCP receptors were normalized to the stratum radiatum of the CA1 region of the hippocampal formation, the ratio of NMDA and TCP binding sites in the forebrain and brain stem

never exceeded 1.2, while in the cerebellar granule cell layer this ratio was greater than 6. On plotting the number of NMDA and TCP receptors against each other and using linear regression, a highly significant correlation was observed (R = 0.95, p < 0.001) (Fig. 2).

The stratum radiatum of the CA1 division of the hippocampal formation contained the highest number of both NMDA and PCP receptors in the CNS. Scatchard analysis of L-3H-glutamate binding revealed a single binding site with a maximum bound value ( $B_{\rm max}$ ) of 9.78  $\pm$  0.84 pmol/mg protein and an association constant ( $K_D$ ) of 158  $\pm$  37 nm (Fig. 3A). <sup>3</sup>H-TCP binding displayed an apparent single binding site with a  $B_{\rm max}$  of 2.07  $\pm$  0.16 pmol/mg protein and  $K_D$  of 127  $\pm$  30 nm (Fig. 3B). When the  $B_{\rm max}$  of NMDA receptors was compared with that of <sup>3</sup>H-TCP labeled receptors, a stoichiometry of 4–5 NMDA to 1 TCP site was determined. Similar values were observed when saturation analyses of binding to layers I–II of cortex were examined.

Comparative distribution of <sup>3</sup>H-glutamate-sensitive NMDA and <sup>3</sup>H-TCP-labeled PCP binding sites

A distinctly "NMDA-like" laminar distribution was recognized for both ligands in the hippocampal formation (Fig. 1E-G). Binding was highest in stratum radiatum, followed by stratum oriens of the CA1/CA2 region (Table 1). Binding in these 2 regions was highly delineated since both of these structures abut the stratum pyramidale, a region of relatively low binding. There was a relatively small number of receptors for both ligands within stratum oriens and stratum radiatum of CA3, which made the boundary between CA1/CA2 and CA3 readily apparent. Both blades of the molecular layer of the dentate gyrus possessed very high densities of binding, while the stratum moleculare/lacunosum of CA1 exhibited intermediate levels.

Densities of binding ranged widely in the cerebral cortex (Table 1). The visual cortex clearly possessed the greatest number of NMDA and TCP receptors, being approximately  $\frac{3}{4}$  as high as the binding in the stratum radiatum (Fig. 1H). High densities were also observed in layers I and II of somatosensory and motor cortices, while layers V and VI of these regions had less than half of the number of binding sites observed in superficial layers (Fig. 1D). In the somatosensory cortex, but not the motor region, an intermediate level of binding was observed as a narrow band in layer IV (Fig. 1D). The anterior cingulate (Fig. 1C) and entorhinal regions (Fig. 1H) possessed equally high levels of binding, which were more than 2 times higher than those in either the retrosplenial cortex (Fig. 1G) or the posterior cingulate gyrus (Fig. 1E).

The basal ganglia and precommissural basal forebrain also revealed heterogeneous patterns of binding. In these regions, however, binding never exceeded 50% of that observed in the densest region of the hippocampus. In the striatum binding was of intermediate density, while the adjacent globus pallidus possessed virtually no binding sites (Fig. 1D). Similarly, the nucleus accumbens and lateral septum possessed nearly equal, intermediate levels of binding, while the closely situated medial septum and horizontal limb of the diagonal band were almost devoid of receptors (Fig. 1C).

Numerous connections have been said to exist between various olfactory regions and the amygdala (Fig. 1, A-G). In this study, with only several exceptions, these regions appeared to possess intermediate to high levels of NMDA and TCP binding. Relatively low levels of binding were measured in the internal granule layer of the olfactory bulb and medial amygdaloid nu-




Table 1. Binding of <sup>3</sup>H-TCP to PCP sites and of <sup>3</sup>H-glutamate to NMDA sites in rat brain

Difactory region   External plexiform layer (EPL)   1069 ± 159   189 ± 46   33     Internal granule layer (IGL)   488 ± 115   57 ± 6   15     Anterior olfactory nucleus (AON)   1368 ± 346   211 ± 43   42     Amygdala   Basolateral, anterior (BLa)   1056 ± 203   141 ± 24   32     Medial (M)   506 ± 165   70 ± 14   15     Posterior cortical (PCoA)   1346 ± 330   176 ± 48   41     Basal ganglia   Caudate-putamen (CPu)   695 ± 161   92 ± 18   21     Globus-pallidus (GP)   75 ± 29   18 ± 6   2     Septal area   Lateral septum (LS)   1060 ± 184   136 ± 25   32     Medial septum (MS)   130 ± 35   35 ± 11   4     Ventral pallidum   Nucleus accumbens (NAc)   849 ± 241   106 ± 18   26     Olfactory tubercle (TU)   1135 ± 290   198 ± 35   35     Cortex   Somatosensory, layers I&II (51 & 2)   2160 ± 381   251 ± 34   66     Somatosensory, layers V&VI (55 & 6)   1038 ± 257   97 ± 18   32     Motor, layers V&VI (M1 & 2)   1932 ± 315   251 ± 36   59     Motor, layers V&VI (M5 & 6)   713 ± 162   97 ± 18   22     Anterior cingulate (ACg)   1830 ± 472   198 ± 34   56     Posterior cingulate (PCg)   752 ± 119   70 ± 15   23     Entorhinal (EC)   1553 ± 299   242 ± 28   48     Primary olfactory (POC)   1548 ± 311   216 ± 33   47     Retrosplenial (Rspl)   884 ± 197   79 ± 15   27     Striate (Str)   2416 ± 256   268 ± 27   74     Hippocampal formation   Dentate gyrus (DG)   2473 ± 262   251 ± 36   76		Ligand bound (fmol/mg protein)		Binding relative to stratum radiatum of CA1 (%)	
External plexiform layer (EPL)	Area	NMDA	TCP	NMDA	TCP
External plexiform layer (EPL)	Olfactory region				
Internal granule layer (IGL)		$1069 \pm 159$	189 ± 46	33	52
Anterior olfactory nucleus (AON)  Amygdala  Basolateral, anterior (BLa)  Medial (M)  Posterior cortical (PCoA)  Basolateral, anterior (BLa)  Medial (M)  Posterior cortical (PCoA)  Basol ganglia  Caudate-putamen (CPu)  Globus-pallidus (GP)  Septal area  Lateral septum (LS)  Medial septum (MS)  Ventral pallidum  Nucleus accumbens (NAc)  Olfactory tubercle (TU)  Cortex  Somatosensory, layers I&II (51 & 2)  Somatosensory, layer III (63)  Somatosensory, layers I&II (13)  Motor, layers V&VI (M5 & 6)  Anterior cingulate (ACg)  Posterior cingulate (PCg)  Primary olfactory (POC)  Retrosplenial (Rspl)  Striate (Str)  Hippocampal formation  Dentate gyrus (DG)  CA1, stratum radiatum (SR)  CA3, stratum oriens (SO)  Retroal (MG)  Posteriol (Royal (MG)  CA3, stratum oriens (SUB)  Tosel  Habenula (HD)  Posteriol (Royal (MG)  Posteriol (Royal (MG)  Retroal (Rspl)  Striate (Str)  Lateral soptum (LS)  Royal (Rspl)  Strate (Str)  Habenula (HD)  Posterior cingulate (PCg)  Stratum radiatum (SR)  CA3, stratum oriens (SO)  CA4, stratum oriens (SO)  CA5  Subsciedum, dorsalis (SUB)  Posterior cingulate (MG)  Posterior cingulate (PCg)  Posterior cingulate (RD)  Retroal (Rspl)  Retroal (Rspl		$488 \pm 115$	$57 \pm 6$	15	16
Basolateral, anterior (BLa)		$1368 \pm 346$	$211 \pm 43$	42	58
Basolateral, anterior (BLa)	Amygdala				
Posterior cortical (PCoA)   1346 ± 330   176 ± 48   41   Basal ganglia   Caudate-putamen (CPu)   695 ± 161   92 ± 18   21   Globus-pallidus (GP)   75 ± 29   18 ± 6   2   Septal area   Lateral septum (LS)   1060 ± 184   136 ± 25   32   Medial septum (MS)   130 ± 35   35 ± 11   4   Ventral pallidum   Nucleus accumbens (NAc)   849 ± 241   106 ± 18   26   Olfactory tubercle (TU)   1135 ± 290   198 ± 35   35   50   20   20   20   20   20   20   2	Basolateral, anterior (BLa)	$1056 \pm 203$	$141 \pm 24$	32	39
Basal ganglia Caudate-putamen (CPu) Globus-pallidus (GP) 75 ± 29 18 ± 6 2 Septal area Lateral septum (LS) Medial septum (MS) 130 ± 35 35 ± 11 4 Ventral pallidum Nucleus accumbens (NAc) Olfactory tubercle (TU) 1135 ± 290 198 ± 35 35 Cortex Somatosensory, layers I&II (51 & 2) Somatosensory, layers I&II (53) Somatosensory, layers V&VI (55 & 6) Motor, layers I&II (M1 & 2) Motor, layers I&II (M1 & 2) Motor, layers I&II (M1 & 2) Motor, layers V&VI (M5 & 6) Posterior cingulate (ACg) Posterior cingulate (PCg) Entorhinal (EC) Primary olfactory (POC) Striate (Str) Primary olfactory (POC) Striate (Str) Dentate gyrus (DG) CA1, stratum radiatum (SR) CA3, stratum radiatum (SR) CA3, stratum oriens (SO) Suberula (AG) Posterior cingulate (SIB) Striate (SUP) CA1/CA3, stratum pyramidale (SP) Suberula (HD) Medial geniculate (MG) Posterior clayers (MD) Medial geniculate (MD) Medial geniculate (MG) Posterior lateral/medial (VPL) Medial dorsal (MD) Medial geniculate (MG) Posterior lateral/medial (VPL) Medial dorsal (MD) Medial geniculate (MG) Posterior lateral/medial (VPL) Reticular (Rt) Other		$506 \pm 165$	$70 \pm 14$	15	19
Caudate-putamen (CPu) 695 ± 161 92 ± 18 21 Globus-pallidus (GP) 75 ± 29 18 ± 6 2 Septal area  Lateral septum (LS) 1060 ± 184 136 ± 25 32 Medial septum (MS) 130 ± 35 35 ± 11 4 Ventral pallidum  Nucleus accumbens (NAc) 849 ± 241 106 ± 18 26 Olfactory tubercle (TU) 1135 ± 290 198 ± 35 35 Cortex  Somatosensory, layers I&II (51 & 2) 2160 ± 381 251 ± 34 66 Somatosensory, layers V&VI (55 & 6) 1038 ± 257 97 ± 18 32 Motor, layers V&VI (M5 & 6) 1184 ± 216 128 ± 19 36 Somatosensory, layers V&VI (M5 & 6) 713 ± 162 97 ± 18 22 Anterior cingulate (ACg) 1830 ± 472 198 ± 34 56 Posterior cingulate (PCg) 752 ± 119 70 ± 15 23 Entorhinal (EC) 1553 ± 299 242 ± 28 48 Primary olfactory (POC) 1548 ± 311 216 ± 33 47 Retrosplenial (Rspl) 884 ± 197 79 ± 15 27 Striate (Str) 2416 ± 256 268 ± 27 74 Hippocampal formation  Dentate gyrus (DG) 2473 ± 262 251 ± 36 76 CA1, stratum radiatum (SR) 2328 ± 367 365 ± 34 100 CA1, stratum radiatum (SR) 2386 ± 327 312 ± 38 89 CA3, stratum oriens (SO) 2886 ± 327 312 ± 38 89 CA3, stratum radiatum (SP) 792 ± 200 97 ± 16 24 Stratum lacunosum/moleculare (SML) 839 ± 268 216 ± 33 56 Subiculum, dorsalis (SUB) 1074 ± 141 97 ± 19 33 Thalamus  Habenula (Hb) 75 ± 44 13 ± 6 2 Lateral dorsal (MD) 902 ± 167 88 ± 17 27 Medial dorsal (MD) 977 ± 168 84 ± 17 30 Medial geniculate (MG) 968 ± 239 92 ± 15 29 Dorsolateral geniculate (DLG) 858 ± 153 106 ± 21 26 Ventral posterior lateral/medial (VPL) 647 ± 178 88 ± 11 19 Reticular (Rt) Other	Posterior cortical (PCoA)	$1346 \pm 330$	$176 \pm 48$	41	49
Globus-pallidus (GP)	Basal ganglia				
Septal area	Caudate-putamen (CPu)	$695 \pm 161$	$92 \pm 18$	21	25
Lateral septum (LS)	Globus-pallidus (GP)	$75 \pm 29$	$18 \pm 6$	2	5
Medial septum (MS)         130 ± 35         35 ± 11         4           Ventral pallidum         Nucleus accumbens (NAc)         849 ± 241         106 ± 18         26           Olfactory tubercle (TU)         1135 ± 290         198 ± 35         35           Cortex         Somatosensory, layers I&II (51 & 2)         2160 ± 381         251 ± 34         66           Somatosensory, layers IWI (53)         1184 ± 216         128 ± 19         36           Somatosensory, layers V&VI (55 & 6)         1038 ± 257         97 ± 18         32           Motor, layers I&II (M1 & 2)         1932 ± 315         251 ± 36         59           Motor, layers V&VI (M5 & 6)         713 ± 162         97 ± 18         32           Motor, layers V&VI (M5 & 6)         713 ± 162         97 ± 18         22           Anterior cingulate (ACg)         1830 ± 472         198 ± 34         56           Posterior cingulate (PCg)         752 ± 119         70 ± 15         23           Entorhinal (EC)         1553 ± 299         242 ± 28         48           Primary olfactory (POC)         1548 ± 311         216 ± 33         47           Retrosplenial (Rspl)         84 ± 197         79 ± 15         27           Striate (Str)         2473 ± 262         251	Septal area				
Ventral pallidum   Nucleus accumbens (NAc)   849 ± 241   106 ± 18   26     Olfactory tubercle (TU)   1135 ± 290   198 ± 35   35     Cortex   Somatosensory, layers I&II (51 & 2)   2160 ± 381   251 ± 34   66     Somatosensory, layer III (53)   1184 ± 216   128 ± 19   36     Somatosensory, layers V&VI (55 & 6)   1038 ± 257   97 ± 18   32     Motor, layers I&II (M1 & 2)   1932 ± 315   251 ± 36   59     Motor, layers V&VI (M5 & 6)   713 ± 162   97 ± 18   22     Anterior cingulate (ACg)   1830 ± 472   198 ± 34   56     Posterior cingulate (PCg)   752 ± 119   70 ± 15   23     Entorhinal (EC)   1553 ± 299   242 ± 28   48     Primary olfactory (POC)   1548 ± 311   216 ± 33   47     Retrosplenial (Rspl)   884 ± 197   79 ± 15   27     Striate (Str)   2416 ± 256   268 ± 27   74     Hippocampal formation     Dentate gyrus (DG)   2473 ± 262   251 ± 36   76     CA1, stratum radiatum (SR)   3238 ± 367   365 ± 34   100     CA3, stratum oriens (SO)   2886 ± 327   312 ± 38   89     CA3, stratum oriens (SO)   2886 ± 327   312 ± 38   89     CA4, stratum oriens (SP)   792 ± 200   97 ± 16   24     Stratum lacunosum/moleculare (SML)   1839 ± 268   216 ± 33   56     Subiculum, dorsalis (SUB)   1074 ± 141   97 ± 19   33     Thalamus     Habenula (Hb)   75 ± 44   13 ± 6   2     Lateral dorsal (LD)   902 ± 167   88 ± 17   27     Medial geniculate (MG)   968 ± 239   92 ± 15   29     Dorsolateral geniculate (DLG)   858 ± 153   106 ± 21   26     Ventral posterior lateral/medial (VPL)   647 ± 178   88 ± 11   19     Reticular (Rt)   0ther	Lateral septum (LS)	$1060 \pm 184$	$136\pm25$	32	38
Nucleus accumbens (NAc) Olfactory tubercle (TU) 1135 ± 290 198 ± 35 35  Cortex  Somatosensory, layers I&II (51 & 2) Somatosensory, layers III (53) 1184 ± 216 128 ± 19 36 Somatosensory, layers V&VI (55 & 6) 1038 ± 257 97 ± 18 32 Motor, layers I&II (M1 & 2) 1932 ± 315 251 ± 36 59 Motor, layers V&VI (M5 & 6) 713 ± 162 77 ± 18 22 Anterior cingulate (ACg) 1830 ± 472 198 ± 34 56 Posterior cingulate (PCg) 752 ± 119 70 ± 15 23 Entorhinal (EC) 1553 ± 299 242 ± 28 88 Primary olfactory (POC) 1548 ± 311 216 ± 33 47 Retrosplenial (Rspl) 884 ± 197 79 ± 15 27 Striate (Str) 2416 ± 256 268 ± 27 74 Hippocampal formation Dentate gyrus (DG) CA1, stratum radiatum (SR) 2473 ± 262 251 ± 36 76 CA2, stratum radiatum (SR) 2328 ± 367 365 ± 34 100 CA3, stratum oriens (SO) 2886 ± 327 312 ± 38 89 CA3, stratum oriens (SO) 2886 ± 327 312 ± 38 89 CA3, stratum oriens (SO) 2886 ± 327 312 ± 38 9 CA3, stratum oriens (SO) 100 ± 169 176 ± 26 32 CA3, stratum oriens (SO) 101 ± 19 29 CA1/CA3, stratum pyramidale (SP) 792 ± 200 97 ± 16 24 Stratum lacunosum/moleculare (SML) Subiculum, dorsalis (SUB) 1074 ± 141 97 ± 19 33 Thalamus Habenula (Hb) 75 ± 44 13 ± 6 2 Lateral dorsal (LD) 902 ± 167 88 ± 17 30 Medial geniculate (MG) 968 ± 239 92 ± 15 99 Dorsolateral geniculate (DLG) 858 ± 153 106 ± 21 26 Ventral posterior lateral/medial (VPL) Reticular (Rt) Other	Medial septum (MS)	$130 \pm 35$	$35 \pm 11$	4	10
Olfactory tubercle (TU)	Ventral pallidum				
Cortex         Somatosensory, layers I&II (51 & 2)         2160 ± 381         251 ± 34         66           Somatosensory, layer III (53)         1184 ± 216         128 ± 19         36           Somatosensory, layers V&VI (55 & 6)         1038 ± 257         97 ± 18         32           Motor, layers I&II (M1 & 2)         1932 ± 315         251 ± 36         59           Motor, layers V&VI (M5 & 6)         713 ± 162         97 ± 18         22           Anterior cingulate (ACg)         1830 ± 472         198 ± 34         56           Posterior cingulate (PCg)         752 ± 119         70 ± 15         23           Entorhinal (EC)         1553 ± 299         242 ± 28         48           Primary olfactory (POC)         1548 ± 311         216 ± 33         47           Retrosplenial (Rspl)         884 ± 197         79 ± 15         27           Striate (Str)         2416 ± 256         268 ± 27         74           Hippocampal formation         2473 ± 262         251 ± 36         76           CA1, stratum radiatum (SR)         3238 ± 367         365 ± 34         100           CA3, stratum oriens (SO)         2886 ± 327         312 ± 38         89           CA3, stratum oriens         946 ± 305         101 ± 19         29	Nucleus accumbens (NAc)	$849 \pm 241$	$106 \pm 18$	26	29
Cortex         Somatosensory, layers I&II (51 & 2)         2160 ± 381         251 ± 34         66           Somatosensory, layer III (53)         1184 ± 216         128 ± 19         36           Somatosensory, layers V&VI (55 & 6)         1038 ± 257         97 ± 18         32           Motor, layers I&II (M1 & 2)         1932 ± 315         251 ± 36         59           Motor, layers V&VI (M5 & 6)         713 ± 162         97 ± 18         22           Anterior cingulate (ACg)         1830 ± 472         198 ± 34         56           Posterior cingulate (PCg)         752 ± 119         70 ± 15         23           Entorhinal (EC)         1553 ± 299         242 ± 28         48           Primary olfactory (POC)         1548 ± 311         216 ± 33         47           Retrosplenial (Rspl)         884 ± 197         79 ± 15         27           Striate (Str)         2416 ± 256         268 ± 27         74           Hippocampal formation         2473 ± 262         251 ± 36         76           CA1, stratum radiatum (SR)         3238 ± 367         365 ± 34         100           CA3, stratum oriens (SO)         2886 ± 327         312 ± 38         89           CA3, stratum oriens         946 ± 305         101 ± 19         29	Olfactory tubercle (TU)	$1135 \pm 290$	$198\pm35$	35	54
Somatosensory, layer III (53)       1184 ± 216       128 ± 19       36         Somatosensory, layers V&VI (55 & 6)       1038 ± 257       97 ± 18       32         Motor, layers I&II (M1 & 2)       1932 ± 315       251 ± 36       59         Motor, layers V&VI (M5 & 6)       713 ± 162       97 ± 18       22         Anterior cingulate (ACg)       1830 ± 472       198 ± 34       56         Posterior cingulate (PCg)       752 ± 119       70 ± 15       23         Entorhinal (EC)       1553 ± 299       242 ± 28       48         Primary olfactory (POC)       1548 ± 311       216 ± 33       47         Retrosplenial (Rspl)       884 ± 197       79 ± 15       27         Striate (Str)       2416 ± 256       268 ± 27       74         Hippocampal formation       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56     <	Cortex				
Somatosensory, layers V&VI (55 & 6)         1038 ± 257         97 ± 18         32           Motor, layers I&II (M1 & 2)         1932 ± 315         251 ± 36         59           Motor, layers V&VI (M5 & 6)         713 ± 162         97 ± 18         22           Anterior cingulate (ACg)         1830 ± 472         198 ± 34         56           Posterior cingulate (PCg)         752 ± 119         70 ± 15         23           Entorhinal (EC)         1553 ± 299         242 ± 28         48           Primary olfactory (POC)         1548 ± 311         216 ± 33         47           Retrosplenial (Rspl)         884 ± 197         79 ± 15         27           Striate (Str)         2416 ± 256         268 ± 27         74           Hippocampal formation         2473 ± 262         251 ± 36         76           CA1, stratum radiatum (SR)         3238 ± 367         365 ± 34         100           CA1, stratum oriens (SO)         2886 ± 327         312 ± 38         89           CA3, stratum oriens (SO)         2886 ± 327         312 ± 38         89           CA3, stratum primidale (SP)         792 ± 200         97 ± 16         24           Stratum lacunosum/moleculare (SML)         1839 ± 268         216 ± 33         56           S	Somatosensory, layers I&II (51 & 2)	$2160 \pm 381$	$251 \pm 34$	66	68
Motor, layers I&II (M1 & 2)       1932 ± 315       251 ± 36       59         Motor, layers V&VI (M5 & 6)       713 ± 162       97 ± 18       22         Anterior cingulate (ACg)       1830 ± 472       198 ± 34       56         Posterior cingulate (PCg)       752 ± 119       70 ± 15       23         Entorhinal (EC)       1553 ± 299       242 ± 28       48         Primary olfactory (POC)       1548 ± 311       216 ± 33       47         Retrosplenial (Rspl)       884 ± 197       79 ± 15       27         Striate (Str)       2416 ± 256       268 ± 27       74         Hippocampal formation       Dentate gyrus (DG)       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum radiatum       1060 ± 169       176 ± 26       32         CA3, stratum oriens       946 ± 305       101 ± 19       29         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56         Subiculum, dorsalis (SUB)       1074 ± 141       97 ± 19       33<		$1184 \pm 216$	$128 \pm 19$	36	35
Motor, layers V&VI (M5 & 6)       713 ± 162       97 ± 18       22         Anterior cingulate (ACg)       1830 ± 472       198 ± 34       56         Posterior cingulate (PCg)       752 ± 119       70 ± 15       23         Entorhinal (EC)       1553 ± 299       242 ± 28       48         Primary olfactory (POC)       1548 ± 311       216 ± 33       47         Retrosplenial (Rspl)       884 ± 197       79 ± 15       27         Striate (Str)       2416 ± 256       268 ± 27       74         Hippocampal formation       70       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum radiatum       1060 ± 169       176 ± 26       32         CA3, stratum oriens       946 ± 305       101 ± 19       29         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56         Subiculum, dorsalis (SUB)       1074 ± 141       97 ± 19       33         Thalamus       44       13 ± 6       2         Lateral dors	Somatosensory, layers V&VI (55 & 6)	$1038 \pm 257$	$97 \pm 18$	32	26
Anterior cingulate (ACg)  Posterior cingulate (PCg)  Posterior cingulate (PCg)  Entorhinal (EC)  Primary olfactory (POC)  Striate (Str)  Hippocampal formation  Dentate gyrus (DG)  CA1, stratum radiatum (SR)  CA3, stratum radiatum  CA3, stratum oriens (SO)  CA1, stratum oriens  CA3, stratum oriens  CA1, stratum oriens  CA1, stratum oriens  CA2, stratum oriens  CA3, stratum oriens  CA3, stratum oriens  CA1, stratum oriens  CA1, stratum oriens  SA3 ± 367  A65 ± 34  A7  A65 ± 34  A7  A67  A67  A68 ± 27  A7  A7  A7  A7  A8  A89  A99  A90  A91  A91  A92  A93  A94  A95  A96  A97  A97  A98  A98  A99  A96  A97  A98  A98  A99  A96  A97  A98  A98  A99  A99  A99  A99  A99	Motor, layers I&II (M1 & 2)	$1932 \pm 315$	$251\pm36$	59	69
Posterior cingulate (PCg) 752 ± 119 70 ± 15 23 Entorhinal (EC) 1553 ± 299 242 ± 28 48 Primary olfactory (POC) 1548 ± 311 216 ± 33 47 Retrosplenial (Rspl) 884 ± 197 79 ± 15 27 Striate (Str) 2416 ± 256 268 ± 27 74  Hippocampal formation  Dentate gyrus (DG) 2473 ± 262 251 ± 36 76 CA1, stratum radiatum (SR) 3238 ± 367 365 ± 34 100 CA1, stratum oriens (SO) 2886 ± 327 312 ± 38 89 CA3, stratum radiatum 1060 ± 169 176 ± 26 32 CA3, stratum oriens 946 ± 305 101 ± 19 29 CA1/CA3, stratum pyramidale (SP) 792 ± 200 97 ± 16 24 Stratum lacunosum/moleculare (SML) 1839 ± 268 216 ± 33 56 Subiculum, dorsalis (SUB) 1074 ± 141 97 ± 19 33  Thalamus  Habenula (Hb) 75 ± 44 13 ± 6 2 Lateral dorsal (LD) 902 ± 167 88 ± 17 27 Medial dorsal (MD) 977 ± 168 84 ± 17 30 Medial geniculate (MG) 968 ± 239 92 ± 15 29 Dorsolateral geniculate (DLG) 858 ± 153 106 ± 21 26 Ventral posterior lateral/medial (VPL) 647 ± 178 88 ± 11 19 Reticular (Rt) 308 ± 119 31 ± 3 9 Other		$713 \pm 162$	$97 \pm 18$	22	27
Posterior cingulate (PCg) 752 ± 119 70 ± 15 23 Entorhinal (EC) 1553 ± 299 242 ± 28 48 Primary olfactory (POC) 1548 ± 311 216 ± 33 47 Retrosplenial (Rspl) 884 ± 197 79 ± 15 27 Striate (Str) 2416 ± 256 268 ± 27 74  Hippocampal formation  Dentate gyrus (DG) 2473 ± 262 251 ± 36 76 CA1, stratum radiatum (SR) 3238 ± 367 365 ± 34 100 CA1, stratum oriens (SO) 2886 ± 327 312 ± 38 89 CA3, stratum radiatum 1060 ± 169 176 ± 26 32 CA3, stratum oriens 946 ± 305 101 ± 19 29 CA1/CA3, stratum pyramidale (SP) 792 ± 200 97 ± 16 24 Stratum lacunosum/moleculare (SML) 1839 ± 268 216 ± 33 56 Subiculum, dorsalis (SUB) 1074 ± 141 97 ± 19 33  Thalamus  Habenula (Hb) 75 ± 44 13 ± 6 2 Lateral dorsal (LD) 902 ± 167 88 ± 17 27 Medial dorsal (MD) 977 ± 168 84 ± 17 30 Medial geniculate (MG) 968 ± 239 92 ± 15 29 Dorsolateral geniculate (DLG) 858 ± 153 106 ± 21 26 Ventral posterior lateral/medial (VPL) 647 ± 178 88 ± 11 19 Reticular (Rt) 308 ± 119 31 ± 3 9 Other		$1830 \pm 472$	$198 \pm 34$	56	54
Entorhinal (EC)		$752 \pm 119$	$70 \pm 15$	23	19
Primary olfactory (POC)       1548 ± 311       216 ± 33       47         Retrosplenial (Rspl)       884 ± 197       79 ± 15       27         Striate (Str)       2416 ± 256       268 ± 27       74         Hippocampal formation       Dentate gyrus (DG)       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum oriens       1060 ± 169       176 ± 26       32         CA3, stratum oriens       946 ± 305       101 ± 19       29         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56         Subiculum, dorsalis (SUB)       1074 ± 141       97 ± 19       33         Thalamus         Habenula (Hb)       75 ± 44       13 ± 6       2         Lateral dorsal (LD)       902 ± 167       88 ± 17       27         Medial dorsal (MD)       977 ± 168       84 ± 17       30         Medial geniculate (MG)       968 ± 239       92 ± 15       29         Dorsolateral geniculate (DLG)       858 ± 153		$1553 \pm 299$	$242 \pm 28$	48	64
Retrosplenial (Rspl)       884 ± 197       79 ± 15       27         Striate (Str)       2416 ± 256       268 ± 27       74         Hippocampal formation       Dentate gyrus (DG)       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum oriens       946 ± 305       101 ± 19       29         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56         Subiculum, dorsalis (SUB)       1074 ± 141       97 ± 19       33         Thalamus         Habenula (Hb)       75 ± 44       13 ± 6       2         Lateral dorsal (LD)       902 ± 167       88 ± 17       27         Medial geniculate (MG)       968 ± 239       92 ± 15       29         Dorsolateral geniculate (DLG)       858 ± 153       106 ± 21       26         Ventral posterior lateral/medial (VPL)       647 ± 178       88 ± 11       19         Reticular (Rt)       308 ± 119<		$1548 \pm 311$		47	59
Striate (Str)       2416 $\pm$ 256       268 $\pm$ 27       74         Hippocampal formation         Dentate gyrus (DG) $2473 \pm 262$ $251 \pm 36$ 76         CA1, stratum radiatum (SR) $3238 \pm 367$ $365 \pm 34$ $100$ CA1, stratum oriens (SO) $2886 \pm 327$ $312 \pm 38$ $89$ CA3, stratum radiatum $1060 \pm 169$ $176 \pm 26$ $32$ CA3, stratum oriens $946 \pm 305$ $101 \pm 19$ $29$ CA1/CA3, stratum pyramidale (SP) $792 \pm 200$ $97 \pm 16$ $24$ Stratum lacunosum/moleculare (SML) $1839 \pm 268$ $216 \pm 33$ $56$ Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ $33$ Thalamus         Habenula (Hb) $75 \pm 44$ $13 \pm 6$ $2$ Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Other     <		$884 \pm 197$	$79 \pm 15$	27	22
Hippocampal formation  Dentate gyrus (DG)		$2416 \pm 256$	$268 \pm 27$	74	73
Dentate gyrus (DG)       2473 ± 262       251 ± 36       76         CA1, stratum radiatum (SR)       3238 ± 367       365 ± 34       100         CA1, stratum oriens (SO)       2886 ± 327       312 ± 38       89         CA3, stratum radiatum       1060 ± 169       176 ± 26       32         CA3, stratum oriens       946 ± 305       101 ± 19       29         CA1/CA3, stratum pyramidale (SP)       792 ± 200       97 ± 16       24         Stratum lacunosum/moleculare (SML)       1839 ± 268       216 ± 33       56         Subiculum, dorsalis (SUB)       1074 ± 141       97 ± 19       33         Thalamus         Habenula (Hb)       75 ± 44       13 ± 6       2         Lateral dorsal (LD)       902 ± 167       88 ± 17       27         Medial dorsal (MD)       977 ± 168       84 ± 17       30         Medial geniculate (MG)       968 ± 239       92 ± 15       29         Dorsolateral geniculate (DLG)       858 ± 153       106 ± 21       26         Ventral posterior lateral/medial (VPL)       647 ± 178       88 ± 11       19         Reticular (Rt)       308 ± 119       31 ± 3       9         Other					
CA1, stratum radiatum (SR) $3238 \pm 367$ $365 \pm 34$ $100$ CA1, stratum oriens (SO) $2886 \pm 327$ $312 \pm 38$ $89$ CA3, stratum radiatum $1060 \pm 169$ $176 \pm 26$ $32$ CA3, stratum oriens $946 \pm 305$ $101 \pm 19$ $29$ CA1/CA3, stratum pyramidale (SP) $792 \pm 200$ $97 \pm 16$ $24$ Stratum lacunosum/moleculare (SML) $1839 \pm 268$ $216 \pm 33$ $56$ Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ $33$ Thalamus         Habenula (Hb) $75 \pm 44$ $13 \pm 6$ $2$ Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$		$2473 \pm 262$	$251 \pm 36$	76	68
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$3238 \pm 367$	$365 \pm 34$	100	100
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$2886 \pm 327$	$312\pm38$	89	85
CA1/CA3, stratum pyramidale (SP) $792 \pm 200$ $97 \pm 16$ 24         Stratum lacunosum/moleculare (SML) $1839 \pm 268$ $216 \pm 33$ 56         Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ 33         Thalamus       T5 $\pm 44$ $13 \pm 6$ 2         Lateral dorsal (Hb) $902 \pm 167$ $88 \pm 17$ 27         Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ 30         Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ 29         Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ 26         Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ 19         Reticular (Rt) $308 \pm 119$ $31 \pm 3$ 9         Other		1060 ± 169	$176 \pm 26$	32	48
Stratum lacunosum/moleculare (SML) $1839 \pm 268$ $216 \pm 33$ $56$ Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ $33$ Thalamus <ul> <li>Habenula (Hb)</li> <li><math>75 \pm 44</math></li> <li><math>13 \pm 6</math></li> <li><math>2</math></li> </ul> Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other	CA3, stratum oriens	$946 \pm 305$	$101 \pm 19$	29	27
Stratum lacunosum/moleculare (SML) $1839 \pm 268$ $216 \pm 33$ $56$ Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ $33$ Thalamus       Thalamus         Habenula (Hb) $75 \pm 44$ $13 \pm 6$ $2$ Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other	CA1/CA3, stratum pyramidale (SP)	$792 \pm 200$	$97 \pm 16$	24	27
Subiculum, dorsalis (SUB) $1074 \pm 141$ $97 \pm 19$ 33         Thalamus       Habenula (Hb) $75 \pm 44$ $13 \pm 6$ 2         Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ 27         Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ 30         Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ 29         Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ 26         Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ 19         Reticular (Rt) $308 \pm 119$ $31 \pm 3$ 9         Other	Stratum lacunosum/moleculare (SML)	$1839 \pm 268$	$216 \pm 33$	56	59
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			$97 \pm 19$	33	26
Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other					
Lateral dorsal (LD) $902 \pm 167$ $88 \pm 17$ $27$ Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other	Habenula (Hb)	$75 \pm 44$	$13 \pm 6$	2	3
Medial dorsal (MD) $977 \pm 168$ $84 \pm 17$ $30$ Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other	• •		$88 \pm 17$		24
Medial geniculate (MG) $968 \pm 239$ $92 \pm 15$ $29$ Dorsolateral geniculate (DLG) $858 \pm 153$ $106 \pm 21$ $26$ Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other					23
Dorsolateral geniculate (DLG) 858 $\pm$ 153 106 $\pm$ 21 26 Ventral posterior lateral/medial (VPL) 647 $\pm$ 178 88 $\pm$ 11 19 Reticular (Rt) 308 $\pm$ 119 31 $\pm$ 3 9 Other					25
Ventral posterior lateral/medial (VPL) $647 \pm 178$ $88 \pm 11$ $19$ Reticular (Rt) $308 \pm 119$ $31 \pm 3$ $9$ Other				26	28
Reticular (Rt) $308 \pm 119$ $31 \pm 3$ 9 Other					24
Other					8
Bed nucleus stria terminalis (BST) $497 \pm 127$ $53 \pm 11$ 15	• •				
		497 ± 127	53 ± 11	15	14
Medial preoptic area (MPOA) $286 \pm 119$ $40 \pm 14$ 8					11
Lateral hypothalamus (LH) $48 \pm 27$ $18 \pm 7$ 1					4
Ventromedial hypothalamus (VH) $84 \pm 31$ $31 \pm 10$ 2					8
Diagonal band, horizontal limb (HDb) $190 \pm 67$ $35 \pm 9$ 6					9
Zona incerta (ZI) $31 \pm 13$ $13 \pm 8$ 1					4

Table 1. Continued

	Ligand bound (fmol/mg protein)		Binding relative to stratum radiatum of CA1 (%)	
Area	NMDA	TCP	NMDA	TCP
Brain stem				
Superior colliculus (SC)	$616 \pm 132$	$53 \pm 10$	18	15
Periaqueductal gray (PAG)	$242 \pm 65$	$40 \pm 6$	8	10
Interpeduncular nucleus (IPn)	$198 \pm 144$	$26 \pm 8$	6	7
Pontine nuclei (Pn)	$110 \pm 101$	$18 \pm 4$	3	5
Substantia nigra (SN)	$163 \pm 87$	$13 \pm 7$	5	4
Cerebellum				
Granule layer (Gnl)	$633\pm97$	$13 \pm 5$	19	3

Values represent the mean ± SEM of 7 animals. <sup>3</sup>H-glutamate concentration was 200 nm. <sup>3</sup>H-TCP concentration was 20 nm. Autoradiography and quantification of autoradiograms was carried out as described in text.

cleus. The external plexiform layer of the olfactory bulb, the lateral anterior olfactory nucleus, the olfactory tubercle, pyramidal layer of cortex, and the basolateral and primary olfactory/posterior amygdaloid nuclei contained 30–60% of the maximum number of NMDA and TCP recognition sites.

In the thalamus (Fig. 1E-G), homogeneous binding was observed in the laterodorsal and mediodorsal nuclei, as well as in the medial and dorsolateral geniculate and the ventroposterolateral nuclei. This density of binding is in sharp contrast to that in the medial habenula, reticular nuclei, and ventrolateral geniculate nuclei (data not shown), which were nearly devoid of binding. Very low levels of binding were also observed in other diencephalic structures (Fig. 1, E, F), including the zona incerta, and the lateral and ventromedial hypothalamus. The telencephalic medial preoptic area (Fig. 1D), which is the anterior continuation of the hypothalamus, contained low but slightly higher levels than the hypothalamus (Fig. 1E). The bed nucleus of the stria terminalis contained slightly higher levels than the medial preoptic area (Fig. 1D).





Figure 2. Scatter-plot of bound values (in fmol/mg protein) of  ${}^{3}$ H-TCP (20 nm) versus bound values for NMDA receptors ( ${}^{3}$ H-glutamate, 200 nm as above). Linear-regression analysis yielded a correlation coefficient of 0.95 (p < 0.001, Pearson product-moment).






Figure 3. Representative Scatchard plots of <sup>3</sup>H-glutamate binding (A) and <sup>3</sup>H-TCP binding (B) in stratum radiatum of the CA1 subfield of the hippocampal formation. Autoradiography for each ligand was performed as described in Materials and Methods. Each point represents specific binding (average of 15 readings minus readings from nearly adjacent sections) incubated in either the presence of 100 µm NMDA for <sup>3</sup>H-glutamate or 20 µm PCP for <sup>3</sup>H-TCP binding.

### Brain stem and cerebellum

In the brain stem, significant densities were observed only in the superior colliculus and periaqueductal gray region (Fig. 1*H*). Interestingly, as has been previously noted, the granule layer of the cerebellum had about 20% of the highest number of NMDA binding sites but had very few TCP binding sites (Fig. 1*I*).

#### **Discussion**

The described distribution of NMDA receptors in the rat brain is in agreement with previous reports (Greenamyre et al., 1985; Monaghan and Cotman, 1985). Each region evaluated receives putative excitatory amino acid inputs (for a review, see Fagg and Foster, 1983). In hippocampal formation, for instance, NMDA receptors are densest in the stratum radiatum of the CA1 division, which has dense neuropil consisting of the apical dendrites of CA1 pyramidal neurons (Lorente de Nó, 1934) upon which terminate fibers originating from the ipsi- and contralateral CA3 regions (Laurberg, 1979; Taxt and Storm-Mathisen, 1984). Both neurochemical (Storm-Mathisen and Iversen, 1979; Skrede and Malthe-Sorenssen, 1981) and physiological (Collingridge et al., 1983a) studies indicate that these pathways use either glutamate or aspartate as their transmitter. In physiological studies, NMDA, quisqualate- and kainate-sensitive glutamate receptors exist on the apical dendrites of CA1 pyramidal neurons (Collingridge et al., 1983b). NMDA elicits longlasting, delayed responses suited for involvement in synaptic plasticity (Collingridge, 1985). Excitatory stimulation of CA1 in vitro induces long-term potentiation (Alger and Tyler, 1976; Dunwiddie and Lynch, 1978), a model of information storage (Swanson et al., 1982). Dendritic responses elicited by excitation of the CA1 input pathways and long-term potentiation are inhibited by specific NMDA antagonists (Collingridge et al., 1983a; Harris et al., 1984; Wigstrom and Gustafsson, 1984).

Various cortical regions are also densely populated with NMDA receptors. Layers I and II of somatosensory cortex, for instance, have more than twice as many NMDA receptors as intermediate and deep layers. Inter- and intrahemispheric corticocortical association fibers, which are thought to be primarily glutamatergic (Stone, 1979; Fonnum et al., 1981; Streit, 1984; Manzoni et al., 1986; Peinado and Mora, 1986), synapse heavily in the superficial and, to a lesser degree, the deep layers (Lorente de Nó, 1933). The excitation of apical dendrites elicited by stimulation of these pathways is inhibited by NMDA antagonists (Thomson et al., 1985), suggesting a role for NMDA receptors in cortical synaptic transmission.

The striatum receives a rich glutamatergic innervation from the cortex (Spencer, 1976; McGeer et al., 1977; Young et al., 1981; Young and Bradford, 1986), which synapses in part on cholinergic interneurons where NMDA and its antagonists modulate the release of ACh (Scatton and Lehmann, 1982; Snell and Johnson, 1986). The hypothalamic nuclei and most brain-stem structures have very few NMDA receptors. L-3H-glutamate binds sites in these areas (Greenamyre et al., 1984; Halpain et al., 1984); thus, they likely mediate actions of other classes of glutamate receptors, such as the quisqualate or kainate receptors.

Dissociative anesthetics affect a number of chemically and physiologically defined systems in the CNS. For instance, they compete at both muscarinic and opiate receptors (Vincent et al., 1978), as well as inhibit high-affinity reuptake of dopamine (Snell and Johnson, 1986), 5-HT (Smith et al., 1977), and nor-

epinephrine (Gear and Heath, 1976). Moreover, PCP interacts with ion channels such as that associated with the nicotinic receptor (Eldefrawi et al., 1982) and certain potassium channels (Albuquerque et al., 1981). The effects of dissociative anesthetics on so many different chemical systems is not surprising in light of the myriad behavior effects they produce.

Until recently, the dissociative anesthetics and the so-called sigma opiates—the compound SKF 10,047 being the prototype) (Martin et al., 1976)—were thought to act at the same site, the PCP/sigma opiate receptor. This assertion was based on binding (Zukin et al., 1983; Mendelsohn et al., 1985) and drug discrimination studies (Herling et al., 1981; Brady et al., 1982). However, recent data have shown that SKF 10,047 binds to 2 separate sites (Largent et al., 1986; Sircar et al., 1986). The high-affinity site, or "sigma receptor," has a distinct pharmacology, and drugs such as haloperidol and 3-[3-hydroxyphenyl]-N-(1-propyl)piperidine display marked inhibitory actions at this site. The low-affinity site has an anatomical distribution distinct from the sigma site. The dissociative anesthetics, including TCP, are very potent inhibitors at this so-called dissociative anesthetic (PCP) site.

Several groups have found that <sup>3</sup>H-TCP binding sites are dense in the dendritic zones of CA1 of the hippocampal formation, with binding highest in the stratum radiatum (Gundlach et al., 1986; Sircar et al., 1986). Minimal binding was noted in the pyramidal cell layer of the hippocampal formation, which possesses a high concentration of non-PCP sigma opiate binding sites (Largent et al., 1986). Very high <sup>3</sup>H-TCP binding was also found in the dentate gyrus, where dissociative anesthetics inhibit the actions of NMDA (Raja and Guyenet, 1982). <sup>3</sup>H-TCP binding in these and other regions paralleled the distribution of NMDA receptors in the cerebral cortex, striatum, and thalamus. The hypothalamus and brain-stem structures, with the exception of the superior colliculus and periaqueductal gray zone, revealed very little binding of either ligand. The greater density of binding in telencephalic versus the more primitive hypothalamic and brain-stem structures is compatible with the cognitive and behavioral abnormalities produced by PCP.

Physiologically, PCP and PCP-like drugs inhibit noncompetitively the excitatory properties of NMDA in the cerebral cortex (Harrison and Simmonds, 1985) and spinal cord (Martin and Lodge, 1985). Like NMDA antagonists, the dissociative anesthetics inhibit long-term potentiation in vitro (Stringer et al., 1983) and in vivo (Stringer et al., 1983; Morris et al., 1986). The dissociative anesthetics also inhibit NMDA-mediated neural destruction (Olney et al., 1986; Weiss et al., 1986) and attenuate NMDA-enhanced release of ACh in the cortex (Lodge and Johnston, 1985). Behavioral studies indicate a unique relationship between NMDA receptors and PCP recognition sites. For instance, animals given the NMDA antagonist 2-amino-5phosphonovalerate behave as if treated with PCP (Koek et al., 1986). Moreover, animals generalize to NMDA antagonists as PCP-like in drug discrimination tests (Willets et al., 1986). These data support the concept that NMDA and PCP bind to the same receptor complex.

The cerebellum was the only region in the rat brain where NMDA and <sup>3</sup>H-TCP receptors were mismatched. NMDA receptors are concentrated in the granule cell layer and to a lesser extent in the molecular layer. Quinolinic acid, a tryptophan metabolite, preferentially stimulates NMDA receptors in the cerebral cortex, compared with those in the cerebellum or spinal cord (Perkins and Stone, 1983). Based on this observation, the

existence of 2 NMDA receptor subtypes has been postulated. The loss of concordance between <sup>3</sup>H-TCP and NMDA binding sites in the cerebellum adds further support to this hypothesis and suggests that the quinolinate-insensitive site may not be linked to a TCP-regulated site. The few <sup>3</sup>H-TCP sites in the granular layer may represent labeling to the lower-affinity TCP site described by Vignon et al. (1986).

The precise mechanism whereby the dissociative anesthetics inhibit the action of the NMDA receptor is unclear. NMDA causes the opening of a voltage-dependent cation channel that is gated by Mg<sup>2+</sup> (Mayer et al., 1984; Nowak et al., 1984). Like PCP, Mg<sup>2+</sup> inhibits noncompetitively the action of NMDA (Nowak et al., 1984; Harrison and Simmonds, 1985). Pharmacological evidence suggests that Mg<sup>2+</sup> and the dissociative anesthetics bind at allosteric sites on the receptor-channel molecule and that both of these sites are distinct from the NMDA recognition site (Harrison and Simmonds, 1985; Martin and Lodge, 1985).

The 4–5:1 stoichiometry of NMDA to <sup>3</sup>H-TCP-labeled receptors suggests that several molecules of glutamate are needed to fully activate the receptor and that the dissociative anesthetics exert their inhibitory influences somewhere near the channel. Like Mg<sup>2+</sup>, ketamine and PCP produce a voltage-dependent blockade of the channel (Honey et al., 1985). Furthermore, it has been shown that <sup>3</sup>H-TCP binding is enhanced in the presence of glutamate (Loo et al., 1986). Thus, the dissociative anesthetics, like Mg<sup>2+</sup>, may bind preferentially near the open channel site. However, pharmacological evidence indicates that Mg<sup>2+</sup> and the dissociative anesthetic binding sites are not identical (Harrison and Simmonds, 1985; Martin and Lodge, 1985).

### References

- Albuquerque, E. X., L. G. Aguayo, J. E. Warnick, H. Weinstein, S. D. Glick, S. Maayani, R. K. Ickowicz, and M. P. Blaustein (1981) The behavioral effects of phencyclidines may be due to their blockade of potassium channels. Proc. Natl. Acad. Sci. USA 12: 7792-7796.
- Alger, B. E., and T. J. Tyler (1976) Long-term and short-term plasticity in the CA1, CA3 and dentate regions of the rat hippocampal slice. Brain Res. 110: 463-480.
- Anis, N. A., S. C. Berry, N. R. Burton, and D. Lodge (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79: 565-575.
- Brady, K. T., R. L. Balster, and E. L. May (1982) Stereoisomers of N-allylnormetazocine: Phencyclidine-like behavioral effects in squirrel monkeys and rats, Science 215: 178–180.
- Burns, R. S., and S. E. Lerner (1976) Phencyclidine: An emerging drug problem. Clin. Toxicol. 9: 473-475.
- Collingridge, G. L. (1985) Long term potentiation in the hippocampus: Mechanisms of initiation and modulation by neurotransmitters. Trends Pharmacol. Sci. 6: 407-411.
- Collingridge, G. L., S. J. Kehl, and H. McLennan (1983a) Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J. Physiol. (Lond.) 334: 33-46.
- Collingridge, G. L., S. J. Kehl, and H. McLennan (1983b) The antagonism of amino acid-induced excitations of rat hippocampal CA1 neurones in vitro. J. Physiol, (Lond.) 334: 19-31.
- Corssen, G., and E. F. Domino (1966) Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth. Analg. 45: 29-40.
- Domino, E. F. (1964) Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int. Rev. Neurobiol. 6: 303-347.
- Duchen, M. R., N. R. Burton, and T. J. Biscoe (1985) An intracellular study of the interactions of N-methyl-DL-aspartate with ketamine in the mouse hippocampal slice. Brain Res. 342: 149–153.
- Dunwiddie, T., and G. Lynch (1978) Long-term potentiation and

- depression of synaptic responses in the rat hippocampus: Localization and frequency dependency. J. Physiol. (Lond.) 276: 353–367.
- Eldefrawi, A. T., E. R. Miller, D. L. Murphy, and M. E. Eldefrawi (1982) [3H]Phencyclidine interactions with the nicotinic acetylcholine receptor channel and its inhibition by psychotropic, antipsychotic, opiate, antidepressant, antibiotic, antiviral, and antiarrhythmic drugs. Mol. Pharmacol. 22: 72–81.
- Engberg, I., J. A. Flatman, and J. D. C. Lambert (1978) The action of N-methyl-D-aspartic and kainic acids on motoneurones with emphasis on conductance changes. Proc. Br. Physiol. Soc. 384P-385P.
- Fagg, G. E., and A. C. Foster (1983) Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 9: 701-719.
- Flatman, J. A., P. C. Schwindt, W. E. Crill, and C. E. Stafstrom (1983) Multiple actions of N-methyl-D-aspartate on cat neocortical neurons in vitro. Brain Res. 266: 169-173.
- Fonnum, F., A. Søreide, I. Kvaile, J. Walker, and I. Walaas (1981) Glutamate in cortical fibers. In *Glutamate as a Neurotransmitter*, G. DiChiara and G. L. Gessa, eds., pp. 29-41, Raven, New York.
- Gear, R. E., and R. G. Heath (1976) The effects of phencyclidine on the uptake of <sup>3</sup>H-catecholamines by rat striatal and hypothalamic synaptosomes. Life Sci. 18: 1105-1110.
- Greenamyre, J. T., J. B. Penney, and A. B. Young (1983) Quantitative autoradiography of L-[3H]glutamate binding to rat brain. Neurosci. Lett. 37: 155–160.
- Greenamyre, J. T., A. B. Young, and J. B. Penney (1984) Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J. Neurosci. 4: 2133-2144.
- Greenamyre, J. T., J. M. M. Olson, J. B. Penney, Jr., and A. B. Young (1985) Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. J. Pharmacol. Exp. Ther. 233: 254–263.
- Greifenstein, F. E., J. Yoshitake, M. DeVault, and J. E. Gajewski (1958) A study of a 1-arylcyclohexylamine for anesthesia. Anaesth. Analg. 37: 283-294.
- Gundlach, A. L., B. L. Largent, and S. H. Snyder (1986) Phencyclidine (PCP) receptors: Autoradiographic location in brain with the selective ligand, [3H]TCP. Brain Res. 386: 266-279.
- Halpain, S., C. M. Wieczorek, and T. C. Rainbow (1984) Localization of L-glutamate receptors in rat brain by quantitative autoradiography. J. Neurosci. 4: 2247–2258.
- Harris, E. W., A. H. Ganong, and C. W. Cotman (1984) Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res. 323: 132-137.
- Harrison, N. L., and M. A. Simmonds (1985) Quantitative studies on some antagonists of N-methyl-D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 84: 381-391.
- Herling, S., E. H. Coale, Jr., D. W. Hein, G. Winger, and J. H. Woods (1981) Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrorphan in the pigeon. Psychopharmacology 73: 286-291.
- Honey, C. R., Z. Miljkovic, and J. F. MacDonald (1985) Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci. Lett. 61: 135-139.
- Johnstone, M., V. Evans, and S. Baigel (1959) Sernyl (CI-395) in clinical anesthesia. Br. J. Anaesth. 31: 433-439.
- Kessler, M., G. Petersen, H. M. Vu, M. Baudry, and G. Lynch (1987) L-Phenyl-alanyl-L-glutamate-stimulated, chloride-dependent glutamate binding represents glutamate sequestration mediated by an exchange system. J. Neurochem. 48: 1191-2000.
- Koek, W., E. Kleer, P. J. Mudar, and J. H. Woods (1986) Phencyclidine-like catalepsy induced by the excitatory amino acid antagonist DL-2-amino-5-phosphonovalerate. Behav. Brain Res. 19: 257-259.
- Largent, B. L., A. L. Gundlach, and S. H. Snyder (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[³H]SKF 10,047, (+)-[³H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [³H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharmacol. Exp. Ther. 238: 739–748.
- Laurberg, S. (1979) Commissural and intrinsic connections of the rat hippocampus. J. Comp. Neurol. 184: 685-708.
- Lodge, D., and G. A. R. Johnston (1985) Effect of ketamine on amino acid-evoked release of acetylcholine from rat cerebral cortex in vitro. Neurosci. Lett. 56: 371-375.
- Loo, P., A. Braunwalder, J. Lehmann, and M. Williams (1986) Ra-

- dioligand binding to central phencyclidine sites is dependent on excitatory amino acid receptor agonists. Eur. J. Pharmacol. 123: 467–468
- Lorente de Nó, R. (1933) Studies on the structure of the cerebral cortex. The Area Entorhinais. J. Psychol. Neurol. 45: 381–438.
- Lorente de Nó, R. (1934) Studies on the structure of the cerebral cortex. Continuation of the study of the ammonic system. J. Psychol. Neurol. 46: 113-117.
- Luby, E. D., B. D. Cohen, G. Rosenbaum, J. S. Gottleb, and R. Kelley (1959) Study of a new schizophrenomimetic drug—Sernyl. Arch. Neurol. Psychiatr. 81: 363-369.
- MacDonald, J. F., A. V. Porietis, and J. M. Wojtowicz (1982) L-Aspartic acid induces a region of negative slope conductance in the current-voltage relationship of cultured spinal cord neurons. Brain Res. 237: 248-253.
- Manzoni, T., P. Barbaresi, and M. Fabri (1986) D-[3H]Aspartate retrograde labelling of association neurones in area SI of the cat. Neurosci, Lett. 67: 175–180.
- Maragos, W. F., D. C. M. Chu, J. T. Greenamyre, J. B. Penney, and A. B. Young (1986) High correlation between the localization of [3H]TCP binding and NMDA receptors. Eur. J. Pharmacol. 123: 173–174.
- Martin, D., and D. Lodge (1985) Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 24: 999–1003.
- Martin, W. R., C. G. Fades, J. A. Thompson, R. E. Huppler, and P. E. Gilbert (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-532.
- Mayer, M. L., G. L. Westbrook, and P. B. Guthrie (1984) Voltage-dependent block by Mg<sup>2+</sup> of NMDA responses in spinal cord neurones. Nature 309: 261–263.
- McGeer, P. L., E. G. McGeer, U. Scherer, and K. Singh (1977) A glutamatergic corticostriatal path? Brain Res. 128: 369-373.
- Meldrum, B. (1985) Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin. Sci. 68: 113-122.
- Mendelsohn, L. G., V. Kalra, B. G. Johnson, and G. A. Kerchner (1985) Sigma opioid receptor: Characterization and co-identity with the phencyclidine receptor. J. Pharmacol. Exp. Ther. 233: 597-602.
- Monaghan, D. T., and C. W. Cotman (1985) Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain. J. Neurosci. 5: 2909-2919.
- Morris, R. G. M., E. Anderson, G. S. Lynch, and M. Baudry (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319: 774-776.
- Munson, P. J., and D. Rodbard (1980) Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 220–239.
- Nowak, L., P. Bregestovski, P. Ascher, A. Herbert, and A. Prochiantz (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307: 462-465.
- Olney, J. W., M. T. Price, T. A. Fuller, J. Labruyere, L. Samson, M. Carpenter, and K. Mahan (1986) The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics. Neurosci. Lett. 68: 29-34.
- Pan, H. S., K. A. Frey, A. B. Young, and J. B. Penney (1983) Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography. J. Neurosci. 3: 1189–1198.
- Paxinos, G., and C. Watson (1982) The Rat Brain in Stereotaxic Coordinates, Academic, New York.
- Peinado, J. M., and F. Mora (1986) Glutamic acid as a putative transmitter of the interhemispheric corticocortical connections in the rat. J. Neurochem. 47: 1598–1603.
- Perkins, M. N., and T. W. Stone (1983) Quinolinic acid: Regional variations in neuronal sensitivity. Brain Res. 259: 172–176.
- Quirion, R., R. P. Hammer, Jr., M. Herkenham, and C. B. Pert (1981) Phencyclidine (angel dust)/σ"opiate" receptor: Visualization by tritium-sensitive film. Proc. Natl. Acad. Sci. USA 78: 5881-5885.
- Raja, S. N., and P. G. Guyenet (1982) Action of phencyclidine on synaptic transmission in the hippocampus. Brain Res. 236: 289-304.
- Scatton, B., and J. Lehmann (1982) N-methyl-D-aspartate-type receptors mediate striatal <sup>3</sup>H-acetylcholine release evoked by excitatory amino acids. Nature 297: 422–424.

- Sircar, R., and S. R. Zukin (1985) Quantitative localization of [3H]TCP binding in rat brain by light microscopy autoradiography. Brain Res. 344: 142-145.
- Sircar, R., R. Nichtenhauser, J. R. Ieni, and S. R. Zukin (1986) Characterization and autoradiographic visualization of (+)-[³H]SKF10,047 binding in rat and mouse brain: Further evidence for phencyclidine/ "sigma opiate" receptor commonality. J. Pharmacol. Exp. Ther. 237: 681–688.
- Skrede, K. K., and D. Malthe-Sorenssen (1981) Differential release of D-[<sup>3</sup>H]aspartate and [<sup>14</sup>C]-γ-aminobutyric acid following activation of commissural fibers in a longitudinal slice preparation of guineapig hippocampus. Neurosci. Lett. 21: 71–76.
- Smith, R. C., H. Y. Meltzer, R. C. Arora, and J. M. Davis (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem. Pharmacol. 26: 1435–1439.
- Snell, L. D., and K. M. Johnson (1986) Characterization of the inhibition of excitatory amino acid-induced neurotransmitter release in the rat striatum by phencyclidine-like drugs. J. Pharmacol. Exp. Ther. 238: 938-946.
- Spencer, H. J. (1976) Antagonism of cortical excitation of striatal neurons by glutamic acid diethyl ester: Evidence for glutamic acid as a neurotransmitter in the rat striatum. Brain Res. 102: 91-101.
- Stone, T. W. (1979) Amino acids as neurotransmitters of corticofugal neurones in the rat: A comparison of glutamate and aspartate. Br. J. Pharmacol. 67: 545-551.
- Storm-Mathisen, J., and L. L. Iversen (1979) Uptake of [3H]glutamic acid in excitatory nerve endings: Light and electron microscopic observations in the hippocampal formation of the rat. Neuroscience 4: 1237-1253.
- Streit, P. (1984) Glutamate and aspartate as transmitter candidates for systems of the cerebral cortex. In *Cerebral Cortex*, Vol. 2, E. G. Jones and A. Peters, eds., pp. 119–143, Plenum, New York.
- Stringer, J. L., L. J. Greenfield, J. T. Hackett, and P. G. Guyenet (1983) Blockade of long-term potentiation by phencyclidine and  $\sigma$  opiates in the hippocampus in vivo and in vitro. Brain Res. 280: 127-138.
- Swanson, L. W., T. J. Teyler, and R. F. Thompson (1982) Hippocampal long-term potentiation: Mechanisms and implications for memory. Neurosci. Res. Prog. Bull. 20: 613–769.
- Taxt, T., and J. Storm-Mathisen (1984) Uptake of D-aspartate and L-glutamate in excitatory axon terminals in hippocampus: Autoradiographic and biochemical comparison with  $\gamma$ -aminobutyrate and other amino acids in normal rats and in rats with lesions. Neuroscience 11: 79–100.
- Thomson, A. M., D. C. West, and D. Lodge (1985) An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: A site of action of ketamine? Nature 313: 479-481.
- Vignon, J., R. Chicheportiche, M. Chicheportiche, J. M. Kamenka, P. Geneste, and M. Lazdunski (1983) [3H]TCP: A new tool with high affinity for the PCP receptor in rat brain. Brain Res. 280: 194-197.
- Vignon, J., A. Privat, I. Chaudieu, A. Thierry, J. M. Kamenka, and R. Chicheportiche (1986) [3H]Thienyl-phencyclidine ([3H]TCP) binds to two different sites in rat brain. Localization by autoradiographic and biochemical techniques. Brain Res. 378: 133-141.
- Vincent, J. P., D. Cavey, J. M. Kamenka, P. Geneste, and M. Lazdunski (1978) Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system. Brain Res. 152: 176-182.
- Watkins, J. C., and R. H. Evans (1981) Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. 21: 165-204.
- Weiss, J., M. P. Goldberg, and D. W. Choi (1986) Ketamine protects cultured neocortical neurons from hypoxic injury. Brain Res. 380: 186-190.
- Wigstrom H., and B. Gustafsson (1984) A possible correlate of the postsynaptic condition for long-lasting potentiation in the guinea pig hippocampus in vitro. Neurosci. Lett. 44: 327–332.
- Willets, J., M. Y. Chapman, and R. L. Balster (1986) Discriminative stimulus effects of 2-amino-7-phosphonoheptanoic acid in phencyclidine-trained rats. Soc. Neurosci. Abstr. 12: 909.
- Young, A. B., M. B. Bromberg, and J. B. Penney, Jr. (1981) Decreased glutamate uptake in subcortical areas deafferented by sensorimotor cortical ablation in the cat. J. Neurosci. 3: 241–249.
- Young, A. M. J., and H. F. Bradford (1986) Excitatory amino acid neurotransmitters in the corticostriate pathway: Studies using intracerebral microdialysis in vivo. J. Neurochem. 47: 1399–1404.

Zilles, K. (1985) The Cortex of the Rat: A Stereotaxic Atlas, Springer-Verlag, New York.
Zukin, S. R., M. L. Fitz-Syage, R. Nichtenhauser, and R. S. Zukin

(1983) Specific binding of [3H]phencyclidine in rat central nervous tissue: Further characterization and technical considerations. Brain Res. 258: 277-284.